Suppr超能文献

中国cblC和mut亚型甲基丙二酸血症患者的长期随访

Long-term follow-up of Chinese patients with methylmalonic acidemia of the cblC and mut subtypes.

作者信息

Hao Lili, Ling Shiying, Ding Si, Qiu Wenjuan, Zhang Huiwen, Zhang Kaichuang, Chen Ting, Gu Xuefan, Liang Lili, Han Lianshu

机构信息

Department of Pediatric Endocrinology and Genetic Metabolism, Xinhua Hospital, Shanghai Institute for Pediatric Research, Shanghai Jiaotong University School of Medicine, Shanghai, China.

出版信息

Pediatr Res. 2025 May;97(6):2010-2019. doi: 10.1038/s41390-024-03581-x. Epub 2024 Sep 21.

Abstract

BACKGROUND

Methylmalonic acidemia (MMA) is the most common organic acidemia in China, with cblC (cblC-MMA) and mut (mut-MMA) being the predominant subtypes. The present study aimed to investigate the prognostic manifestations and their possible influence in patients with these two subtypes.

METHODS

A national multicenter retrospective study of patients with cblC-MMA and mut-MMA between 2004 and 2022 was performed. We compared the clinical features between patients with two subtypes or diagnosed with or without newborn screening (NBS) and further explored the potentially influential factors on the prognosis.

RESULTS

The 1617 enrolled MMA patients included 81.6% cblC-MMA patients and 18.4% mut-MMA patients, with an overall poor prognosis rate of 71.9%. These two subtypes of patients showed great differences in poor prognostic manifestations. The role of NBS in better outcomes was more pronounced in cblC-MMA patients. Predictors of outcomes are "pre-treatment onset", "NBS", variants of c.80A > G and c.482G > A and baseline levels of propionylcarnitine and homocysteine for cblC-MMA; "pre-treatment onset", "responsive to vitB12", variants of c.914T > C and baseline propionylcarnitine and propionylcarnitine/acetylcarnitine ratio for mut-MMA. Besides, prognostic biochemical indicators have diagnostic value for poor outcomes in mut-MMA.

CONCLUSIONS

The study provided potential predictors of the long-term outcome of patients with cblC-MMA and mut-MMA.

IMPACT

Predictors of outcomes are "pre-treatment onset", "NBS", MMACHC variants of c.80A > G and c.482G > A and baseline propionylcarnitine and homocysteine for cblC-MMA, "pre-treatment onset", "responsive to vitB12", MMUT variants of c.914T > C and baseline propionylcarnitine and propionylcarnitine/acetylcarnitine ratio for mut-MMA. This study with larger sample sizes effectively validated the prediction power and emphasized the importance of NBS in improving the outcomes of both MMA subtypes. The study enhances understanding of the phenotypic and prognostic variations of MMA disease and the predictors will help in the improvement of diagnosis and treatment strategies to achieve a better prognosis for MMA.

摘要

背景

甲基丙二酸血症(MMA)是中国最常见的有机酸血症,其中cblC型(cblC-MMA)和mut型(mut-MMA)为主要亚型。本研究旨在调查这两种亚型患者的预后表现及其可能的影响因素。

方法

对2004年至2022年间的cblC-MMA和mut-MMA患者进行了一项全国多中心回顾性研究。我们比较了两种亚型患者或经新生儿筛查(NBS)诊断与未诊断患者的临床特征,并进一步探讨了对预后有潜在影响的因素。

结果

纳入的1617例MMA患者中,cblC-MMA患者占81.6%,mut-MMA患者占18.4%,总体预后不良率为71.9%。这两种亚型的患者在预后不良表现上存在很大差异。NBS对改善预后的作用在cblC-MMA患者中更为明显。cblC-MMA患者预后的预测因素为“治疗前发病”“NBS”、c.80A>G和c.482G>A变异以及丙酰肉碱和同型半胱氨酸的基线水平;mut-MMA患者预后的预测因素为“治疗前发病”“对维生素B12有反应”、c.914T>C变异以及丙酰肉碱基线水平和丙酰肉碱/乙酰肉碱比值。此外,预后生化指标对mut-MMA患者的不良预后具有诊断价值。

结论

本研究为cblC-MMA和mut-MMA患者的长期预后提供了潜在的预测因素。

影响

cblC-MMA患者预后的预测因素为“治疗前发病”“NBS”、c.80A>G和c.482G>A的MMACHC变异以及丙酰肉碱和同型半胱氨酸基线水平;mut-MMA患者预后的预测因素为“治疗前发病”“对维生素B12有反应”、c.914T>C的MMUT变异以及丙酰肉碱基线水平和丙酰肉碱/乙酰肉碱比值。本研究样本量较大,有效验证了预测能力,并强调了NBS对改善两种MMA亚型预后的重要性。该研究增进了对MMA疾病表型和预后变异的理解,这些预测因素将有助于改进诊断和治疗策略,以实现MMA更好的预后。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验